Structural modelling and in silico pharmacology of β-carboline alkaloids as potent 5-HT1A receptor antagonists and reuptake inhibitors

被引:29
|
作者
Ayipo, Yusuf Oloruntoyin [1 ,2 ]
Alananzeh, Waleed A. [1 ]
Ahmad, Iqrar [3 ]
Patel, Harun [3 ]
Mordi, Mohd Nizam [1 ]
机构
[1] Univ Sains Malaysia, Ctr Drug Res, George Town 11800, Malaysia
[2] Kwara State Univ, Dept Chem & Ind Chem, Ilorin, Nigeria
[3] RC Patel Inst Pharmaceut Educ & Res, Dept Pharmaceut Chem, Shirpur, Maharashtra, India
来源
关键词
Major depressive disorder; structural modelling; molecular pharmacology; molecular dynamics; drug design; FORCE-FIELD; PROTEIN; DOCKING; RECOGNITION; COVERAGE; ERRORS;
D O I
10.1080/07391102.2022.2104376
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Serotonin (5-HT) antagonists and reuptake inhibitors (SARIs) are atypical antidepressants for managing major depressive disorder. They are oftentimes applied as adjuvants for ameliorating aftereffects of SSRI antidepressants including insomnia and sexual dysfunction. The few available candidates of this class including lorpiprazole and trazodone also display some daunting side effects, making a continuous search for improved alternatives essential. Natural beta-carboline alkaloids (N beta Cs) are interestingly renowned with broad pharmacological spectrum against several neuropsychiatric disorders including depression. However, their potentials as SARIs remain underexplored. In this study, 982 N beta Cs retrieved from the Ambinter-Greenpharma (Amb) database were virtually screened for potent SARI alternatives using computational and biocheminformatics approaches: homology modelling of 5-HT1A receptor, Glide HTVS, SP and XP molecular docking, molecular dynamics (MD) simulation, ADMET and mutagenicity predictions. The homology receptor was validated as a good representative of human 5HT1A receptor using the RCSB structure validation and quality protocols. From the virtual screening against the 5-HT1A receptor, Amb ligands, Amb18709727 and Amb37857532 showed higher binding affinities by XP scores of -8.725 and -7.976 kcal/mol, and MMGBSA of -87.972 and -107.585 kcal/mol respectively compared to lorpiprazole, a reference SARI with XP score and MMGBSA of -6.512 and -62.788 kcal/mol respectively. They maintained ideal contacts with pharmacologically essential amino acid residues implicated in SARI mechanisms and expressed higher stability and compactness than lorpiprazole throughout the trajectories of 100 ns MD simulation. They also displayed interesting ADME, druggability, low toxicity and mutagenicity profiles, ideal for CNS drug prospects, thus, recommended as putative SARI candidates for further study.
引用
收藏
页码:6219 / 6235
页数:17
相关论文
共 50 条
  • [1] Interaction studies of 5-HT1A receptor antagonists and selective 5-HT reuptake inhibitors in isolated aggressive mice
    Sanchez, C
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 334 (2-3) : 127 - 132
  • [2] 3,4-dihydro-2H-benzoxazinones are 5-HT1A receptor antagonists with potent 5-HT reuptake inhibitory activity
    Atkinson, PJ
    Bromidge, SM
    Duxon, MS
    Gaster, LM
    Hadley, MS
    Hammond, B
    Johnson, CN
    Middlemiss, DN
    North, SE
    Price, GW
    Rami, HK
    Riley, GJ
    Scott, CM
    Shaw, TE
    Starr, KR
    Stemp, G
    Thewlis, KM
    Thomas, DR
    Thompson, M
    Vong, AKK
    Watson, JM
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (03) : 737 - 741
  • [3] Development of 5-HT1A receptor antagonists
    Routledge, C
    BEHAVIOURAL BRAIN RESEARCH, 1996, 73 (1-2) : 153 - 156
  • [4] Design and synthesis of new potent, silent 5-HT1A antagonists by covalent coupling of aminopropanol derivatives with selective serotonin reuptake inhibitors
    Perez, M
    Pauwels, PJ
    Pallard-Sigogneau, I
    Fourrier, C
    Chopin, P
    Palmier, C
    Colovray, V
    Halazy, S
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (23) : 3423 - 3428
  • [5] Novel 5-HT1A/1B/1D receptors antagonists with potent 5-HT reuptake inhibitory activity
    Serafinowska, Halina T.
    Blaney, Frank E.
    Lovell, Peter J.
    Merlo, Giancarlo G.
    Scott, Claire M.
    Smith, Paul W.
    Starr, Kathryn R.
    Watson, Jeannette M.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (20) : 5581 - 5585
  • [6] 5-HT1A receptor antagonists and lordosis behavior
    Uphouse, L
    Andrade, M
    CaldarolaPastuszka, M
    Jackson, A
    NEUROPHARMACOLOGY, 1996, 35 (04) : 489 - 495
  • [7] THE DESIGN OF SELECTIVE 5-HT1A RECEPTOR ANTAGONISTS
    CLIFFE, IA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1993, 206 : 30 - MEDI
  • [8] Indoloxypropanolamine analogues as 5-HT1A receptor antagonists
    Krushinski, Joseph H., Jr.
    Schaus, John M.
    Thompson, Dennis C.
    Calligaro, David O.
    Nelson, David L.
    Luecke, Susan H.
    Wainscott, David B.
    Wong, David T.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (20) : 5600 - 5604
  • [9] Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists
    Ward, Simon E.
    Eddershaw, Peter J.
    Scott, Claire M.
    Gordon, Laurie J.
    Lovell, Peter J.
    Moore, Susan H.
    Smith, Paul W.
    Starr, Kathryn R.
    Thewlis, Kevin M.
    Watson, Jeannette M.
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (10) : 2887 - 2890
  • [10] Involvement of presynaptic 5-HT1A and benzodiazepine receptors in the anticonflict activity of 5-HT1A receptor antagonists
    Wesolowska, A
    Paluchowska, M
    Chojnacka-Wójcik, E
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 471 (01) : 27 - 34